Table 1.
Clinical characteristic of 20 patients enrolled
| Baseline characteristics | |
|---|---|
| Age, years | 70 [65.3–75.3] |
| Gender, male | 16 (80) |
| BMI | 30.5 [27-32.9] |
| SAPS II | 41 [34.5–59.3] |
| Charlson Comorbidity Index | 4.5 [2–5] |
| CHD | 6 (30) |
| COPD | 7 (35) |
| Diabetes | 8 (40) |
| CKD | 4 (20) |
| Immunosuppression | 1 (5) |
| Presenting Features & CRRT | |
| VAP | 20 (100) |
| Concomitant bacteremia | 6 (30) |
| Septic Shock | 13(80) |
| ARDS | 18 (90) |
| SOFA | 9 [6.7–11] |
| BAL Acinetobacter spp. isolation | 20 (100) |
| Colisitn MIC mcg/mL | 1[1-1.5] |
| Serum albumin, g/dL | 2.1 [2-2.3] |
| Fluid balance, mL | + 651.5 [323–797.5] |
| Hematocrit, % | 28 [27–29] |
| Residual diuresis, mL/24 h | 0 |
| CVVHDF dose intensity, mL/kg/h | 32.5 [30–35] |
| CRRT duration, days | 12.5 [10–23.25] |
| Outcome measures & Therapy | |
| MV duration, days | 26 [21.25–37.25] |
| Vasopressors duration, days | 6.5 [4.5-11.25] |
| Death in ICU | 15 (75) |
| Treatment failure | 14 (70) |
| Renal Recovery* | 6 (37.5) |
| Nebulized colistin therapy | 18 (90) |
| Intravenous colistimethate therapy, days | 13 [9.25-12] |
Categorical variables are expressed in count (percentage); continuous variables are expressed as median [interquartile range]
Abbreviations: BMI: body mass index; VAP: Ventilator Associated Pneumonia; SAPS II: Simplified Acute Physiology Score II; CHD: Chronic Heart Disease; COPD: Chronic Obstructive Pulmonary Disease; CKD: Chronic Kidney Disease; MV: mechanical ventilation; ICU: Intensive Care Unit; ARDS: Acute Respiratory Distress Syndrome; SOFA: Sequential Organ Failure Assessment; BAL: bronchoalveolar lavage; BSI: Blood Stream Infection; MIC: Minimal Inhibitory Concentration; CRRT: continuous renal replacement therapy; CVVHDF: continuous veno-venous haemodiafiltration
*The rate of renal recovery was computed from the 16 patients without chronic renal failure